Skip to main content
Article thumbnail
Location of Repository

InterAKTions with FKBPs - mutational and pharmacological exploration

By Anne-Katrin Fabian, Andreas März, Sonja Neimanis, Ricardo M. Biondi, Christian Kozany and Felix Hausch

Abstract

The FK506-binding protein 51 (FKBP51) is an Hsp90-associated co-chaperone which regulates steroid receptors and kinases. In pancreatic cancer cell lines, FKBP51 was shown to recruit the phosphatase PHLPP to facilitate dephosphorylation of the kinase Akt, which was associated with reduced chemoresistance. Here we show that in addition to FKBP51 several other members of the FKBP family bind directly to Akt. FKBP51 can also form complexes with other AGC kinases and mapping studies revealed that FKBP51 interacts with Akt via multiple domains independent of their activation or phosphorylation status. The FKBP51-Akt1 interaction was not affected by FK506 analogs or Akt active site inhibitors, but was abolished by the allosteric Akt inhibitor VIII. None of the FKBP51 inhibitors affected AktS473 phosphorylation or downstream targets of Akt. In summary, we show that FKBP51 binds to Akt directly as well as via Hsp90. The FKBP51-Akt interaction is sensitive to the conformation of Akt1, but does not depend on the FK506-binding pocket of FKBP51. Therefore, FKBP inhibitors are unlikely to inhibit the Akt-FKBP-PHLPP network

Topics: ddc:570, ddc:610
Year: 2013
OAI identifier: oai:publikationen.ub.uni-frankfurt.de:27180

Suggested articles

Citations

  1. (1989). A cytosolic binding protein for the immunosuppressant FK506 has peptidyl-prolyl isomerase activity but is distinct from cyclophilin.
  2. (2004). A physical and functional map of the human TNF-alpha/NF-kappa B signal transduction pathway.
  3. (2009). A PP2A regulatory subunit regulates C. elegans insulin/IGF-1 signaling by modulating AKT-1 phosphorylation.
  4. (2003). Akt as a mediator of cell death.
  5. (2012). An ATP-site on-off switch that restricts phosphatase accessibility of Akt.
  6. (2009). An ATPcompetitive mammalian target of rapamycin inhibitor reveals rapamycinresistant functions of mTORC1.
  7. (1997). Characterization of a 3-phosphoinositide-dependent protein kinase which phosphorylates and activates protein kinase Balpha.
  8. (2003). Crystal structure of an inactive Akt2 kinase domain.
  9. (2010). Crystal structure of human AKT1 with an allosteric inhibitor reveals a new mode of kinase inhibition.
  10. (1999). Crystal structure of the cytoplasmic domain of the type I TGF beta receptor in complex with FKBP12.
  11. (2008). Drug discovery approaches targeting the PI3K/Akt pathway in cancer.
  12. (2010). Facile Synthesis of a Fluorescent Cyclosporin A Analogue To Study Cyclophilin 40 and Cyclophilin 18 Ligands.
  13. (2005). FK1706, a novel non-immunosuppressive immunophilin: neurotrophic activity and mechanism of action.
  14. (2008). FK506 binding protein mediates glioma cell growth and sensitivity to rapamycin treatment by regulating NF-kappaB signaling pathway.
  15. (2005). FK506-binding proteins 51 and 52 differentially regulate dynein interaction and nuclear translocation of the glucocorticoid receptor in mammalian cells.
  16. (2012). FKBP5 as a selection biomarker for gemcitabine and Akt inhibitors in treatment of pancreatic cancer.
  17. (2009). FKBP51 affects cancer cell response to chemotherapy by negatively regulating Akt.
  18. (2010). FKBP51 and Cyp40 are positive regulators of androgen-dependent prostate cancer cell growth and the targets of FK506 and cyclosporin A.
  19. (2010). FKBP51 promotes assembly of the Hsp90 chaperone complex and regulates androgen receptor signaling in prostate cancer cells.
  20. (2009). Fluorescent probes to characterise FK506-binding proteins.
  21. (2007). Identification of inhibitors of protein kinase B using fragment-based lead discovery.
  22. (2009). Inhibitor hijacking of Akt activation.
  23. (1996). Mechanism of activation of protein kinase B by insulin and IGF-1.
  24. (2000). Modulation of Akt kinase activity by binding to
  25. (2002). Molecular mechanism for the regulation of protein kinase B/Akt by hydrophobic motif phosphorylation.
  26. (2010). mTORC2 can associate with ribosomes to promote cotranslational phosphorylation and stability of nascent Akt polypeptide.
  27. (2005). PHLPP: a phosphatase that directly dephosphorylates Akt, promotes apoptosis, and suppresses tumor growth.
  28. phosphorylation and activity of serum- and glucocorticoid-regulated kinase-
  29. (2005). Phosphorylation and regulation of Akt/PKB by the rictor-mTOR complex.
  30. (2010). Physiological regulation of Akt activity and stability.
  31. (2008). Regulation of phosphorylation of Thr-308 of Akt, cell proliferation, and survival by the B55alpha regulatory subunit targeting of the protein phosphatase 2A holoenzyme to Akt.
  32. (2009). Role of a novel PH-kinase domain interface in PKB/Akt regulation: structural mechanism for allosteric inhibition.
  33. Romano MF (2010) FK506-binding protein 51 is a possible novel tumoral marker.
  34. (2007). Signal Responsiveness of I{kappa}B Kinases Is Determined by Cdc37-assisted Transient Interaction with Hsp90.
  35. (2012). Small moleculeinduced cytosolic activation of protein kinase Akt rescues ischemia-elicited neuronal death.
  36. (1998). Specific binding of tetratricopeptide repeat proteins to the C-terminal 12-kDa domain of hsp90.
  37. (2008). Structure-based classification of 45 FK506-binding proteins.
  38. (2011). Targeting FKBP isoforms with smallmolecule ligands.
  39. (2011). The chemical biology of immunophilin ligands.
  40. (1990). The cytosolic-binding protein for the immunosuppressant FK-506 is both a ubiquitous and highly conserved peptidyl-prolyl cis-trans isomerase.
  41. (2003). The Hsp90-binding peptidylprolyl isomerase FKBP52 potentiates glucocorticoid signaling in vivo.
  42. (2007). The immunophilin ligands cyclosporin A and FK506 suppress prostate cancer cell growth by androgen receptor-dependent and -independent mechanisms.
  43. (2010). The nuts and bolts of AGC protein kinases.
  44. (2010). The PI3K pathway as drug target in human cancer.
  45. (2001). The PIF-binding pocket in PDK1 is essential for activation of S6K and SGK, but not PKB.
  46. (2012). The Prospect of FKBP51 as a Drug Target.
  47. (1993). Two FKBPrelated proteins are associated with progesterone receptor complexes.

To submit an update or takedown request for this paper, please submit an Update/Correction/Removal Request.